IL106217A - Pharmaceutical compositions containing organic nitrites for vasodilator therapy - Google Patents

Pharmaceutical compositions containing organic nitrites for vasodilator therapy

Info

Publication number: IL106217A
Authority: IL; Israel
Prior art keywords: nitrite; dosage form; nitrites; composition; organic
Prior art date: 1992-07-02

Application number

IL106217A

Other languages

English (en)

Other versions

IL106217A0 (en

Original Assignee

Baker Norton Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-02

Filing date

1993-07-02

Publication date

1998-04-05

1993-07-02 Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma

1993-11-15 Publication of IL106217A0 publication Critical patent/IL106217A0/xx

1998-04-05 Publication of IL106217A publication Critical patent/IL106217A/en

Links

238000002560 therapeutic procedure Methods 0.000 title claims abstract description 29
229940124549 vasodilator Drugs 0.000 title claims abstract description 21
239000003071 vasodilator agent Substances 0.000 title claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 title claims description 9
150000002826 nitrites Chemical class 0.000 title description 16
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims abstract description 63
206010019280 Heart failures Diseases 0.000 claims abstract description 46
206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 45
239000002552 dosage form Substances 0.000 claims abstract description 34
206010002383 Angina Pectoris Diseases 0.000 claims abstract description 26
239000002674 ointment Substances 0.000 claims abstract description 21
238000001990 intravenous administration Methods 0.000 claims abstract description 17
206010020772 Hypertension Diseases 0.000 claims abstract description 16
238000011161 development Methods 0.000 claims abstract description 12
230000007774 longterm Effects 0.000 claims abstract description 12
239000002775 capsule Substances 0.000 claims abstract description 7
201000001881 impotence Diseases 0.000 claims abstract description 6
208000023589 ischemic disease Diseases 0.000 claims abstract description 6
230000001225 therapeutic effect Effects 0.000 claims abstract 3
238000001802 infusion Methods 0.000 claims description 39
-1 alkyl nitrites Chemical class 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 19
APNSGVMLAYLYCT-UHFFFAOYSA-N isobutyl nitrite Chemical compound CC(C)CON=O APNSGVMLAYLYCT-UHFFFAOYSA-N 0.000 claims description 15
OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 10
239000003826 tablet Substances 0.000 claims description 7
230000037317 transdermal delivery Effects 0.000 claims description 6
239000007894 caplet Substances 0.000 claims description 5
DCUDQJHBYBOPCQ-UHFFFAOYSA-N (3-chloro-2,2-dimethylpropyl) nitrite Chemical compound ClCC(C)(C)CON=O DCUDQJHBYBOPCQ-UHFFFAOYSA-N 0.000 claims description 4
UYFFAINCSURFJZ-UHFFFAOYSA-N 2-phenylethyl nitrite Chemical compound O=NOCCC1=CC=CC=C1 UYFFAINCSURFJZ-UHFFFAOYSA-N 0.000 claims description 4
206010002388 Angina unstable Diseases 0.000 claims description 4
208000007814 Unstable Angina Diseases 0.000 claims description 4
KTQDPHRNUFXDJB-UHFFFAOYSA-N cyclohexylmethyl nitrite Chemical compound O=NOCC1CCCCC1 KTQDPHRNUFXDJB-UHFFFAOYSA-N 0.000 claims description 4
201000004332 intermediate coronary syndrome Diseases 0.000 claims description 4
229940100611 topical cream Drugs 0.000 claims 2
229940100640 transdermal system Drugs 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 14
238000012377 drug delivery Methods 0.000 abstract description 9
230000001684 chronic effect Effects 0.000 abstract description 8
208000007718 Stable Angina Diseases 0.000 abstract description 5
239000008280 blood Substances 0.000 abstract description 5
210000004369 blood Anatomy 0.000 abstract description 5
230000000699 topical effect Effects 0.000 abstract description 4
239000006189 buccal tablet Substances 0.000 abstract description 3
239000006071 cream Substances 0.000 abstract description 3
239000007935 oral tablet Substances 0.000 abstract description 3
239000007921 spray Substances 0.000 abstract description 3
239000006190 sub-lingual tablet Substances 0.000 abstract description 3
241000700159 Rattus Species 0.000 description 31
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 26
229960003711 glyceryl trinitrate Drugs 0.000 description 24
230000000694 effects Effects 0.000 description 23
239000000006 Nitroglycerin Substances 0.000 description 22
230000002861 ventricular Effects 0.000 description 15
238000011282 treatment Methods 0.000 description 12
230000000144 pharmacologic effect Effects 0.000 description 9
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
229940079593 drug Drugs 0.000 description 8
150000002823 nitrates Chemical class 0.000 description 8
229910002651 NO3 Inorganic materials 0.000 description 7
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 7
230000036772 blood pressure Effects 0.000 description 6
210000002216 heart Anatomy 0.000 description 6
230000009467 reduction Effects 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
206010019233 Headaches Diseases 0.000 description 5
230000002411 adverse Effects 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
231100000869 headache Toxicity 0.000 description 5
230000000004 hemodynamic effect Effects 0.000 description 5
210000005240 left ventricle Anatomy 0.000 description 5
230000036316 preload Effects 0.000 description 5
230000000747 cardiac effect Effects 0.000 description 4
210000004351 coronary vessel Anatomy 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
206010052804 Drug tolerance Diseases 0.000 description 3
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
208000002173 dizziness Diseases 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000001435 haemodynamic effect Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000004165 myocardium Anatomy 0.000 description 3
229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 3
208000007530 Essential hypertension Diseases 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010030124 Oedema peripheral Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
208000001431 Psychomotor Agitation Diseases 0.000 description 2
206010037423 Pulmonary oedema Diseases 0.000 description 2
206010038743 Restlessness Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
229960003116 amyl nitrite Drugs 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000011340 continuous therapy Methods 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
238000013265 extended release Methods 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
229960003132 halothane Drugs 0.000 description 2
230000007574 infarction Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
229960000201 isosorbide dinitrate Drugs 0.000 description 2
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
206010009192 Circulatory collapse Diseases 0.000 description 1
206010009866 Cold sweat Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010073310 Occupational exposures Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010041277 Sodium retention Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000003257 anti-anginal effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
210000001765 aortic valve Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
238000013131 cardiovascular procedure Methods 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000004283 incisor Anatomy 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003601 intercostal effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
229960003827 isosorbide mononitrate Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000005246 left atrium Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
238000007726 management method Methods 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960004027 molsidomine Drugs 0.000 description 1
XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229960002460 nitroprusside Drugs 0.000 description 1
231100000675 occupational exposure Toxicity 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
208000011818 severe chest pain Diseases 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
150000004072 triols Chemical class 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000009724 venous congestion Effects 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
230000002618 waking effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL106217A 1992-07-02 1993-07-02 Pharmaceutical compositions containing organic nitrites for vasodilator therapy IL106217A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/908,224 US5278192A (en)	1992-07-02	1992-07-02	Method of vasodilator therapy for treating a patient with a condition

Publications (2)

Publication Number	Publication Date
IL106217A0 IL106217A0 (en)	1993-11-15
IL106217A true IL106217A (en)	1998-04-05

Family

ID=25425396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL106217A IL106217A (en)	1992-07-02	1993-07-02	Pharmaceutical compositions containing organic nitrites for vasodilator therapy

Country Status (19)

Country	Link
US (2)	US5278192A (2)
EP (1)	EP0604642A1 (2)
JP (1)	JP2729333B2 (2)
KR (1)	KR0170789B1 (2)
CN (1)	CN1086997A (2)
AU (1)	AU667948B2 (2)
CA (1)	CA2116785C (2)
CZ (1)	CZ39894A3 (2)
HU (1)	HUT70501A (2)
IL (1)	IL106217A (2)
MX (1)	MX9303982A (2)
NO (1)	NO305886B1 (2)
NZ (1)	NZ254490A (2)
OA (1)	OA09890A (2)
PL (1)	PL302613A1 (2)
SK (1)	SK23594A3 (2)
TW (1)	TW261530B (2)
WO (1)	WO1994001103A1 (2)
ZA (1)	ZA934771B (2)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5646181A (en) *	1992-07-02	1997-07-08	Research Foundation Of State University Of New York	Method and compositions for treating impotence
US5278192A (en) *	1992-07-02	1994-01-11	The Research Foundation Of State University Of New York	Method of vasodilator therapy for treating a patient with a condition
GB9311920D0 (en)	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
US5973011A (en) *	1994-03-30	1999-10-26	Isis Pharma Gmbh	Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
US5681278A (en) *	1994-06-23	1997-10-28	Cormedics Corp.	Coronary vasculature treatment method
US5594032A (en) *	1994-11-10	1997-01-14	Gonzalez-Cadavid; Nestor F.	Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5665077A (en) *	1995-04-24	1997-09-09	Nitrosci Pharmaceuticals Llc	Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis
US5645839A (en) *	1995-06-07	1997-07-08	Trustees Of Boston University	Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US5658936A (en) *	1995-09-18	1997-08-19	Brigham & Women's Hospital, Inc.	Enhancement of erectile function with renin-angiotensin system inhibitors
US5897880A (en)	1995-09-29	1999-04-27	Lam Pharmaceuticals, Llc.	Topical drug preparations
US6036977A (en) *	1995-09-29	2000-03-14	L.A.M. Pharmaceutical Corp.	Drug preparations for treating sexual dysfunction
US6387407B1 (en)	1995-09-29	2002-05-14	L.A.M. Pharmaceutical Corporation	Topical drug preparations
US6251436B1 (en)	1995-09-29	2001-06-26	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
AU2252297A (en) *	1996-01-31	1997-08-22	Technology Licensing Co., L.L.C.	Method of diagnosis and treatment and related compositions and apparatus
US6258032B1 (en) *	1997-01-29	2001-07-10	William M. Hammesfahr	Method of diagnosis and treatment and related compositions and apparatus
GB9608408D0 (en)	1996-04-23	1996-06-26	Adams Michael A	Treatment of erectile dysfunction
US5797887A (en) *	1996-08-27	1998-08-25	Novovasc Llc	Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
US5958884A (en) *	1997-04-11	1999-09-28	The Brigham And Women's Hospital, Inc.	Compositions and methods for treating erectile dysfunction
US6191156B1 (en)	1997-04-11	2001-02-20	The Brigham And Women's Hospital, Inc.	Compositions and methods for treating bladder dysfunction
ZA989356B (en) *	1997-10-16	1998-11-16	Isis Pharma Gmbh	Pharmaceutical preparations
US6056966A (en) *	1998-05-18	2000-05-02	Baker Norton Pharmaceuticals, Inc.	Method and compositions for treating impotence
US7045152B2 (en)	1999-09-08	2006-05-16	Duke University	Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US6314956B1 (en)	1999-09-08	2001-11-13	Duke University	Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
CA2410632A1 (en)	2000-06-22	2001-12-27	David S. Garvey	Nitrosated and nitrosylated taxanes, compositions and methods of use
EA005649B1 (ru) *	2000-08-11	2005-04-28	Дэвид Р. Уитлок	Композиции, содержащие аммиакокисляющие бактерии, увеличивающие продуцирование окиси азота и предшественников окиси азота, и способы их использования
US20020172712A1 (en) *	2001-03-19	2002-11-21	Alan Drizen	Antiemetic, anti-motion sustained release drug delivery system
AU2002258798A1 (en) *	2001-04-13	2002-10-28	Children's Hospital Medical Center	Methods for the treatment of hepatic disorders
US20030027793A1 (en) *	2001-05-08	2003-02-06	Thomas Lauterback	Transdermal treatment of parkinson's disease
US20030026830A1 (en) *	2001-05-08	2003-02-06	Thomas Lauterback	Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030138494A1 (en) *	2001-05-15	2003-07-24	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
US20040225275A1 (en) *	2001-08-02	2004-11-11	Reynolds James Dixon	Fetal physiology during maternal surgery or diagnosis
US6676855B2 (en) *	2001-08-02	2004-01-13	Duke University	Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
WO2003057380A2 (en) *	2002-01-11	2003-07-17	Whitlock David R	Compositions including ammonia oxidizing bacteria and methods of using same
AU2003210808A1 (en)	2002-03-06	2003-09-22	Duke University	Methods and composition based on discovery of metabolism of nitroclycerin
US7776925B2 (en) *	2002-03-06	2010-08-17	Duke University	Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria
US20060263419A1 (en) *	2002-03-12	2006-11-23	Hans-Michael Wolff	Transdermal therapeutic system for Parkinson's Disease
US8822473B2 (en) *	2002-05-21	2014-09-02	Gilead Sciences, Inc.	Method of treating diabetes
MXPA04011530A (es)	2002-05-21	2005-08-15	Cv Therapeutics Inc	Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes.
US6936639B2 (en) *	2002-08-21	2005-08-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Nitroxyl progenitors in the treatment of heart failure
WO2005063221A1 (en) *	2003-12-19	2005-07-14	Duke University	Measuring vasodilating activity of blood samples to track disease course
EP1865770A4 (en) *	2005-04-07	2010-12-29	Nitromed Inc	ASSESSMENT OF GENETIC RISK IN CARDIAC ERRORS: IMPACT OF THE GENETIC VARIATION OF NOS3
CA2610922A1 (en) *	2005-06-13	2006-12-21	Yeda Research And Development Co. Ltd.	Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases
WO2007041681A2 (en) *	2005-10-04	2007-04-12	Nitromed, Inc.	Methods for treating respiratory disorders
WO2007106034A1 (en) *	2006-03-14	2007-09-20	Lars E Gustafsson	New method for the manufacture of therapeutic compounds and compositions, compounds and compositions produced therewhith, and their use
US7625852B2 (en) *	2006-06-07	2009-12-01	Henry Hadry	Nail polish remover
US9259535B2 (en)	2006-06-22	2016-02-16	Excelsior Medical Corporation	Antiseptic cap equipped syringe
US11229746B2 (en)	2006-06-22	2022-01-25	Excelsior Medical Corporation	Antiseptic cap
EP2219657A4 (en)	2007-11-15	2020-01-08	Louisiana State University	USE OF NITRITE SALTS IN CHRONIC ISCHEMIA
US9849276B2 (en)	2011-07-12	2017-12-26	Pursuit Vascular, Inc.	Method of delivering antimicrobial to a catheter
US9078992B2 (en)	2008-10-27	2015-07-14	Pursuit Vascular, Inc.	Medical device for applying antimicrobial to proximal end of catheter
US20120237617A1 (en)	2009-06-18	2012-09-20	Theravasc Inc.	Use of nitrite salts in treating tissue damage
CA2777066C (en) *	2009-10-14	2020-02-18	TheraVasc, LLC	Pharmaceutical formulations of nitrite and uses thereof
WO2011063339A1 (en) *	2009-11-23	2011-05-26	Cardioxyl Pharmaceuticals, Inc.	Nitroxyl donors for the treatment of pulmonary hypertension
US20110144067A1 (en) *	2009-12-07	2011-06-16	Toscano John P	N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives
WO2011071947A2 (en)	2009-12-07	2011-06-16	Johns Hopkins University	Bis-acylated hydroxylamine derivatives
US10166381B2 (en)	2011-05-23	2019-01-01	Excelsior Medical Corporation	Antiseptic cap
CA2881726A1 (en) *	2012-08-23	2014-02-27	Cardiolynx Ag	Extended release compositions of an aminoalkyl nitrate
CA2899602C (en)	2013-02-20	2024-01-30	Theravasc Inc.	Pharmaceutical uses of inorganic nitrites
KR102607213B1 (ko)	2014-04-15	2023-11-30	에이오바이오미 엘엘씨	암모니아-산화 니트로소모나스 유트로파 균주 d23
US11225640B2 (en)	2014-04-15	2022-01-18	Aobiome Llc	Ammonia oxidizing bacteria for treatment of psoriasis
ES2755352T3 (es)	2014-05-02	2020-04-22	Excelsior Medical Corp	Paquete en tira para tapón antiséptico
DK3294404T3 (da)	2015-05-08	2025-09-08	Icu Medical Inc	Medicinske konnektorer konfigureret til at modtage emittere af terapeutiske midler
PL3525865T3 (pl)	2016-10-14	2023-02-06	Icu Medical, Inc.	Nasadki dezynfekcyjne dla łączników medycznych
WO2018204206A2 (en)	2017-05-01	2018-11-08	Icu Medical, Inc.	Medical fluid connectors and methods for providing additives in medical fluid lines
US11541220B2 (en)	2018-11-07	2023-01-03	Icu Medical, Inc.	Needleless connector with antimicrobial properties
US11400195B2 (en)	2018-11-07	2022-08-02	Icu Medical, Inc.	Peritoneal dialysis transfer set with antimicrobial properties
US11541221B2 (en)	2018-11-07	2023-01-03	Icu Medical, Inc.	Tubing set with antimicrobial properties
US11534595B2 (en)	2018-11-07	2022-12-27	Icu Medical, Inc.	Device for delivering an antimicrobial composition into an infusion device
US11517732B2 (en)	2018-11-07	2022-12-06	Icu Medical, Inc.	Syringe with antimicrobial properties
JP2022513096A (ja)	2018-11-21	2022-02-07	アイシーユー・メディカル・インコーポレーテッド	リング及びインサートを有するキャップを備える抗菌装置
GB2579240B (en) *	2018-11-27	2020-12-16	Attgeno Ab	New processes, compositions and medical uses
GB202007929D0 (en) *	2020-05-27	2020-07-08	Attgeno Ab	New medical uses
WO2022072663A1 (en) *	2020-10-01	2022-04-07	Emergent Product Development Gaithersburg Inc.	Stabilized alkyl nitrite compositions
JP2024500319A (ja)	2020-12-07	2024-01-09	アイシーユー・メディカル・インコーポレーテッド	腹膜透析キャップ、システム、及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3106511A (en) *	1961-12-14	1963-10-08	Revlon	Amyl nitrite inhalant composition
CA1163195A (en) *	1980-06-26	1984-03-06	Alec D. Keith	Polymeric diffusion matrix containing a vasodilator
US4450175A (en) *	1982-09-23	1984-05-22	Warshaw Thelma G	Method and compositions for treating acne
DE3305690A1 (de) *	1983-02-18	1984-08-30	Heinrich Mack Nachf., 7918 Illertissen	Glycerinmononitrate zur behandlung der angina pectoris
US4751087A (en) *	1985-04-19	1988-06-14	Riker Laboratories, Inc.	Transdermal nitroglycerin delivery system
US4681584A (en) *	1985-05-03	1987-07-21	Alza Corporation	Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4615699A (en) *	1985-05-03	1986-10-07	Alza Corporation	Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
JPH06696B2 (ja) *	1987-01-27	1994-01-05	積水化学工業株式会社	テ−プ製剤
JPH06697B2 (ja) *	1987-01-27	1994-01-05	積水化学工業株式会社	テ−プ製剤
US4956181A (en) *	1987-05-08	1990-09-11	Eastman Kodak	Nitrate therapy for angina pectoris
US5278192A (en) *	1992-07-02	1994-01-11	The Research Foundation Of State University Of New York	Method of vasodilator therapy for treating a patient with a condition

1992
- 1992-07-02 US US07/908,224 patent/US5278192A/en not_active Expired - Fee Related
1993
- 1993-06-30 CA CA002116785A patent/CA2116785C/en not_active Expired - Fee Related
- 1993-06-30 NZ NZ254490A patent/NZ254490A/xx unknown
- 1993-06-30 CZ CZ94398A patent/CZ39894A3/cs unknown
- 1993-06-30 US US08/199,280 patent/US5489610A/en not_active Expired - Fee Related
- 1993-06-30 AU AU46587/93A patent/AU667948B2/en not_active Ceased
- 1993-06-30 SK SK235-94A patent/SK23594A3/sk unknown
- 1993-06-30 WO PCT/US1993/006235 patent/WO1994001103A1/en not_active Ceased
- 1993-06-30 HU HU9400627A patent/HUT70501A/hu unknown
- 1993-06-30 JP JP6503397A patent/JP2729333B2/ja not_active Expired - Fee Related
- 1993-06-30 EP EP93916879A patent/EP0604642A1/en not_active Withdrawn
- 1993-06-30 PL PL93302613A patent/PL302613A1/xx unknown
- 1993-06-30 KR KR1019940700689A patent/KR0170789B1/ko not_active Expired - Fee Related
- 1993-07-01 MX MX9303982A patent/MX9303982A/es not_active IP Right Cessation
- 1993-07-02 ZA ZA934771A patent/ZA934771B/xx unknown
- 1993-07-02 CN CN93116247A patent/CN1086997A/zh active Pending
- 1993-07-02 IL IL106217A patent/IL106217A/en not_active IP Right Cessation
- 1993-08-20 TW TW082106738A patent/TW261530B/zh active
1994
- 1994-02-28 OA OA60477A patent/OA09890A/en unknown
- 1994-02-28 NO NO940691A patent/NO305886B1/no unknown

Also Published As

Publication number	Publication date
EP0604642A1 (en)	1994-07-06
CA2116785A1 (en)	1994-01-20
OA09890A (en)	1994-09-15
NO940691L (no)	1994-03-18
CN1086997A (zh)	1994-05-25
ZA934771B (en)	1994-01-20
US5278192A (en)	1994-01-11
AU667948B2 (en)	1996-04-18
US5489610A (en)	1996-02-06
IL106217A0 (en)	1993-11-15
PL302613A1 (en)	1994-09-05
NZ254490A (en)	1997-08-22
CA2116785C (en)	1998-04-07
JPH06510800A (ja)	1994-12-01
WO1994001103A1 (en)	1994-01-20
HU9400627D0 (en)	1994-06-28
TW261530B (2)	1995-11-01
NO305886B1 (no)	1999-08-16
AU4658793A (en)	1994-01-31
SK23594A3 (en)	1994-08-10
CZ39894A3 (en)	1994-11-16
HUT70501A (en)	1995-10-30
NO940691D0 (no)	1994-02-28
JP2729333B2 (ja)	1998-03-18
KR0170789B1 (ko)	1999-02-01
MX9303982A (es)	1994-02-28

Legal Events

Date	Code	Title
1998-10-30	FF	Patent granted
1999-01-26	KB	Patent renewed
1999-12-22	KB	Patent renewed
2004-03-28	RH1	Patent not in force

Publication	Publication Date	Title
US5489610A (en)	1996-02-06	Sustained release organic nitrite therapy
Boden et al.	1985	Nifedipine-lnduced hypotension and myocardial ischemia in refractory angina pectoris
Calne et al.	1971	Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa
US20090203792A1 (en)	2009-08-13	Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators
JP3119430B2 (ja)	2000-12-18	水酸基ラジカル消去剤
JPS5888312A (ja)	1983-05-26	カルニチンまたは低級アシルカルニチンからなる静脈疾患治療剤
RU2306924C1 (ru)	2007-09-27	Способ коррекции эндотелиальной дисфункции комбинацией лозартана и резвератрола при l-name-индуцированном дефиците оксида азота
JPS6129927B2 (2)	1986-07-10
RU2302241C1 (ru)	2007-07-10	Способ коррекции эндотелиальной дисфункции комбинацией индапамида и резвератрола при l-name-индуцированном дефиците оксида азота
RU2245147C2 (ru)	2005-01-27	Применение ингибитора вазопептидазы для лечения стенокардии
CN113662930B (zh)	2022-08-09	二蒽酮类化合物在制备预防和/或治疗心肌缺血性疾病及其相关病症的药物中的应用
Zanzinger et al.	1994	Novel organic nitrates are potent dilators of large coronary arteries with reduced development of tolerance during long-term infusion in dogs: role of the sulfhydryl moiety
IE46491B1 (en)	1983-06-29	Pharmaceutical compositions
RU2153871C2 (ru)	2000-08-10	Способ подготовки больных к проведению коронарографии
SU1664323A1 (ru)	1991-07-23	Кардиопротекторное средство "Милдронат
US5326774A (en)	1994-07-05	Pharmaceutical preparation of antihypertensive, antianginal, antiarrhythmic and antiglaucomic action
JPS60155115A (ja)	1985-08-15	血圧上昇剤
LEVY	1938	Drugs in the treatment of heart disease
SU1503819A1 (ru)	1989-08-30	Способ лечени сердечной недостаточности
JPS61200917A (ja)	1986-09-05	ベタキソロールとニフエジピンとを含有する医薬組成物
EP1621193A2 (en)	2006-02-01	Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators
Atkins	1989	Nitroglycerin explosions, tolerance, and myths
JPH03251540A (ja)	1991-11-11	血管拡張剤
CA2277479A1 (en)	1998-07-16	Use of diadenosine polyphosphates for reducing blood pressure
JPS59204119A (ja)	1984-11-19	心筋梗塞症治療用製剤